Advancing colorectal cancer management through clinical proteomics: from genotype to proteotype toward clinical translation.

Authors

P Ramachandran, C S Y Chen, C S Lee, T T Aye, A Kunjukunju, M H Elias, A R Mydin, T Y Low

Published in

Expert review of proteomics. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, with outcomes depending on the stages at diagnosis. Genomic and transcriptomic classifications are largely inferential because the genotype-phenotype relationship is non-linear and is influenced by post-translational regulation, protein turnover, and the tumor microenvironment (TME). Proteomics measures this functional layer directly.
This review surveys proteomic technologies for CRC emphasizing mass spectrometry, affinity- and aptamer- based multiplex platforms, post-translational modification proteomics, spatial proteomics, AI-driven structural and predictive analysis, and multi-omics integration. Each platform is evaluated based on clinical questions, the supporting evidence and the barriers to implementation. Literature was drawn primarily from PubMed/MEDLINE and Scopus (2020-2026), emphasizing advanced and translational applications.
Alongside approved blood cfDNA and stool-RNA molecular tests, proteomics is a functional complementary technology that may improve biological interpretation, assay triage and treatment response prediction, although prospective clinical utility remains to be established. The decisive barriers are standardized biospecimens, validation evidence, clinical utility data and interoperable public data sharing. (169 words).

PMID:
42876326
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.